This is a landmark approval for RVMD, the first targeted RAS inhibitor for pancreatic cancer with unprecedented survival data. The stock has already appreciated significantly (market cap $45B) but the commercial opportunity is large given the high unmet need. Watch for: (1) initial prescription uptake and payer coverage in coming weeks, (2) EMA phased review timeline for EU approval, (3) expansion into NSCLC (Phase 3 registrational program ongoing), and (4) potential for label expansion into earlier lines of therapy.
Drug in focus
RVMD drug pipeline →daraxonrasib
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 (completed with positive results) / pre-NDA
- Time to market
- NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
- Next catalyst
- None dated
What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $215.44entry
- T+1 · 3mo ago +2.65%α +2.00% · $221.15
- T+5 · 3mo ago −2.88%α −2.76% · $209.23
- T+20 · 8w ago −7.23%α −7.46% · $199.86
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior therapy. The Phase 3 RASolute 302 trial showed a 60% reduction in death risk (HR 0.40) and median OS of 13.2 months vs 6.7 months for chemotherapy. This is the first approved targeted RAS inhibitor for pancreatic cancer, a major commercial opportunity for RVMD given the high unmet need and large patient population (~55,000 annual US diagnoses).
Key Facts
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy
- Phase 3 RASolute 302 trial showed 60% reduction in risk of death (HR 0.40; p<0.0001) vs chemotherapy
- Median overall survival 13.2 months with RASONQUE vs 6.7 months with chemotherapy
- Median progression-free survival 7.2 months vs 3.6 months (HR 0.49; p<0.0001)
- First approved targeted RAS(ON) multi-selective inhibitor for pancreatic cancer
- Once-daily oral tablet now available by prescription in the US with (ON)Path patient support program
- Approval does not require companion diagnostic test; covers patients with or without identified RAS mutation
- Breakthrough Therapy Designation and Orphan Drug Designation granted by FDA
- EMA phased review ongoing; Orphan Medicinal Product designation for pancreatic cancer in EU
Financial Impact
First-in-class RAS inhibitor for ~55,000 annual US PDAC diagnoses with 80% metastatic at diagnosis; 5-year survival ~3% in metastatic setting; no prior targeted therapy existed; pricing not disclosed but represents transformative commercial opportunity for $45B market cap company
Risk Factors
- Competition from other RAS inhibitors in development (e.g., Amgen's sotorasib, Mirati's adagrasib, and other RAS multi-selective programs)
- Safety profile includes dermatologic toxicity (86%), stomatitis (57%), diarrhea (63%), and rare but serious GI perforation (0.9%) and ILD/pneumonitis (2.4%)
- Commercial adoption may be slower than expected if physicians are cautious about new targeted therapy in a difficult-to-treat population
- Pricing and reimbursement uncertainty; patient access programs may limit near-term revenue
- Dependence on single product for revenue; pipeline diversification still in clinical stages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351615 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers